Technology | April 17, 2015

Cerner and Qualcomm Collaborate on Home Health Monitoring Network

Qualcomm's 2net Platform will capture patient data from home, transmit it via Cerner's CareAware platform

Cerner, Qualcomm, home health monitoring, 2net, CareAware, EHR

April 17, 2015 — Cerner Corp. and Qualcomm Life Inc. announced an agreement to extend Cerner’s medical device connectivity capabilities beyond the hospital to the home. Cerner will leverage Qualcomm Life’s U.S. Food and Drug Administration (FDA)-listed 2net Platform and Hub to capture data from medical devices and sensors within a patient’s home, and transmit it to Cerner healthcare clients through Cerner’s CareAware device connectivity platform. Through this initiative, care providers can remotely monitor chronically ill patients in near-real time to enable proactive engagement to potentially reduce the risk of an acute care episode.

Qualcomm Life’s 2net Platform collects, stores and aggregates patient data from connected medical devices provided to the patient, such as weight scales, blood pressure monitors and pulse oximeters. These data values will transmit via CareAware to the Cerner Millennium electronic health record (EHR) and are viewable to the patient in HealtheLife, Cerner’s patient engagement solution. Extending CareAware to integrate devices within the home to the patient’s EHR will provide healthcare organizations a more comprehensive view in their efforts to focus on chronic condition management, reduce readmissions and improve patient health and satisfaction.

Qualcomm Life will join Cerner’s CareAware certification program, an initiative that creates alliances between Cerner and medical device manufacturers to better acquire data from devices to integrate with the EHR via CareAware device connectivity architecture.

Agnesian HealthCare is one of the first enterprise clients to implement the combined technologies to remotely monitor and manage at-risk patient populations. “It is increasingly important that providers are monitoring the whole health of an individual, not just at the point of care in the facility,” said Michael DeGeer, DPM, FACPS, FACFAS, vice president of population health management, Agnesian HealthCare. “Remote patient monitoring allows our clinicians to have access to patients’ health data, within the patient’s health record, while they are at home, which will provide the opportunity for clinicians to make informed interventions as needed.”

For more information: www.cerner.com, www.qualcommlife.com

Related Content

EMPRISE Study Shows Empagliflozin Reduces Heart Failure Hospitalization with new data presented at AHA 2018. #AHA18 #AHA2018
News | Heart Failure | November 07, 2018
November 6, 2018 – Initial results from the real-world EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) s
Acute Heart Failure Mortality, Rehospitalizations Reduced With Blood Volume Measurement
News | Heart Failure | November 02, 2018
In a new study, acute heart failure patients who received individualized treatment by blood volume measurement with the...
Daxor Corp. Collaborating With CHF Solutions on Heart Failure Fluid Overload Management

CHF Solutions' Aquadex FlexFlow System

News | Heart Failure | November 01, 2018
November 1, 2018 — Daxor Corp.
NHLBI Pauses CONCERT-HF Heart Failure Trial
News | Heart Failure | October 29, 2018
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, is pausing the...
A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC 2018. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at ACC earlier this year.

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC 2018. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at ACC earlier this year.

Feature | Heart Failure | October 19, 2018
October 19, 2018 — Abbott announced today that the HeartMate 3 Left Ventricular Assist Device (LVAD) has received U.S
Ohio State First in U.S. to Test Shunt Device for Heart Failure
News | Heart Failure | October 04, 2018
The Ohio State University Wexner Medical Center is first in the country to test a new medical device designed to help...
Mitral Regurgitation Volume Reduced at One Year in REDUCE FMR Trial
News | Heart Failure | September 28, 2018
Heart failure patients who received the Carillon Mitral Contour System in the REDUCE FMR clinical trial showed a...
Overlay Init